Statins appear associated with reduced risk of recurrent cardiovascular events in men, women

June 25, 2012

Cholesterol-lowering statin drugs appear to be associated with reduced risk of recurrent cardiovascular events in men and women, but do not appear to be associated with reduced all-cause mortality or stroke in women, according to a report of a meta-analysis published June 25 in the Archives of Internal Medicine, a JAMA Network publication.

Statins have been used to levels for the last 20 years, but most of the clinical trials on the drugs have predominantly enrolled men. There have been conflicting results on the benefits of statins for women with cardiovascular disease compared with men in secondary cardiovascular disease prevention, according to the study background.

Jose Gutierrez, M.D., M.P.H., of Columbia University Medical Center, New York, and colleagues conducted a meta-analysis of 11 clinical trials (a total of 43,191 participants) to examine whether statin therapy was more effective than placebo in preventing recurrence of cardiovascular events and all-cause mortality in men and women. Researchers also sought to determine the sex-specific effect of statins on the risk of recurrent cardiac and cerebrovascular events.

"In our results, statin therapy reduced the recurrence rate of any type of cardiovascular event, all-cause mortality, coronary death, any MI [ or heart attack], cardiac intervention, and any stroke type. The stratification by sex showed no statistically significant risk reduction for women taking statins compared with women taking placebo for the reduction of all-cause mortality and any type of stroke," the authors comment.

However, the authors observe that the results of their meta-analysis "underscore" the low rate of women being enrolled in cardiovascular prevention clinical trials.

"Women represented only a fifth of the studied sample, limiting the strength of our conclusions. In our results, the benefit associated with statin administration in women did not reach statistical significance compared with placebo in at least two outcomes, all-causes mortality and any stroke type. The reason for this difference is uncertain. One possibility is that the small sample size of women limits the power of the study," the authors note.

The authors conclude "this meta-analysis supports the use of statins in women for the secondary prevention of ."

Explore further: Intensive-dose statin therapy associated with increased risk of diabetes

More information: Arch Intern Med. 2012;172[12]:909-919

Related Stories

Recommended for you

Smoking leaves lasting marks on DNA, study finds

September 20, 2016

(HealthDay)—Smoking cigarettes can leave a lasting imprint on human DNA, altering more than 7,000 genes in ways that may contribute to the development of smoking-related diseases, a new study says.

Sleep disorders may influence heart disease risk factors

September 20, 2016

Sleep problems including sleeping too little or too long, may be linked to a variety of factors that may raise the risk for cardiovascular diseases, according to a new American Heart Association scientific statement published ...

Alcohol may damage the heart—at least for some

September 14, 2016

(HealthDay)—You might need to reconsider that nightly glass of wine (or beer, or liquor) because new research suggests that alcohol may not be as healthy for everyone's heart as previously believed.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.